288 related articles for article (PubMed ID: 17624601)
21. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
22. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
23. Personalized prevention in high risk individuals: Managing hormones and beyond.
Evans DG; Howell SJ; Howell A
Breast; 2018 Jun; 39():139-147. PubMed ID: 29610032
[TBL] [Abstract][Full Text] [Related]
24. [Hereditary breast carcinomas pathologist's perspective].
Vincent-Salomon A; Bataillon G; Djerroudi L
Ann Pathol; 2020 Apr; 40(2):78-84. PubMed ID: 32241645
[TBL] [Abstract][Full Text] [Related]
25. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
26. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
27.
Lee A; Moon BI; Kim TH
Ann Lab Med; 2020 Mar; 40(2):114-121. PubMed ID: 31650727
[TBL] [Abstract][Full Text] [Related]
28. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Eerola H; Heikkilä P; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2005; 7(4):R465-9. PubMed ID: 15987451
[TBL] [Abstract][Full Text] [Related]
29. Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
Nixon RM; Duffy SW
J Cancer Epidemiol Prev; 2002; 7(4):205-12. PubMed ID: 12846491
[TBL] [Abstract][Full Text] [Related]
30. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic approaches for women predisposed to breast cancer.
Nathanson KL; Domchek SM
Annu Rev Med; 2011; 62():295-306. PubMed ID: 21034216
[TBL] [Abstract][Full Text] [Related]
32. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
33. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
Calderon-Margalit R; Paltiel O
Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.
Foulkes WD
Fam Cancer; 2006; 5(2):135-42. PubMed ID: 16736282
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
36. Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?
Noruzinia M; Coupier I; Pujol P
Cancer; 2005 Oct; 104(8):1567-74. PubMed ID: 16155942
[TBL] [Abstract][Full Text] [Related]
37. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
38. BRCA mutations in the management of breast cancer: the state of the art.
Narod SA
Nat Rev Clin Oncol; 2010 Dec; 7(12):702-7. PubMed ID: 20956982
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
Eisinger F; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Julian-Reynier C; Sobol H
Int J Oncol; 2001 Jan; 18(1):5-10. PubMed ID: 11115532
[TBL] [Abstract][Full Text] [Related]
40. BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
Kote-Jarai Z; Powles TJ; Mitchell G; Tidy A; Ashley S; Easton D; Assersohn L; Sodha N; Salter J; Gusterson B; Dowsett M; Eeles R
Cancer Lett; 2007 Mar; 247(2):259-65. PubMed ID: 16777318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
